The Syneos Health Podcast cover art

All Episodes

The Syneos Health Podcast — 193 episodes

#
Title
1

Introducing: Conversations on Commercialization

2

Site Realities Series | From Monitor to Strategic Partner: The Evolution of the CRA Role

3

Site Realities Series | Inside the Site Experience: Challenges, Tradeoffs and Opportunities

4

Conversations on Commercialization: Navigating Dermatology’s New Access Landscape with Paul Rittman of Almirall US

5

Functionally Speaking Series: Regulatory Intelligence, Medical Writing and the AI Inflection Point

6

Functionally Speaking Series: Reimagining Site Experience: CRAs, AI and the Future of Functional Models

7

Functionally Speaking Series: Modernizing Safety and Pharmacovigilance, The Human in the Loop

8

Functionally Speaking Series: Clinical Operations for Large Pharma, Navigating Model Evolution With Agility

9

Functionally Speaking Series: FSP for SMID Sponsors, Navigating Complexity with Flexibility and Trust

10

2025 CNS Summit Series: Scaling Psychedelic Medicines Responsibly, A Conversation with Dr. Dan Karlin, CSO, MindMed

11

2025 CNS Summit Series: Revolutionizing Clinical Trials with Virtual Patients, A Conversation with Anzar Abbas, CEO, Brooklyn Health

12

2025 CNS Summit Series: Rewriting the Rules of Neurodegeneration, A Conversation with Arvinas CSO Angela Cacace, PhD

13

CNS Summit Series: Balanced Disruption in Neurology, A Conversation with Merz Therapeutics CEO Stefan König

14

Conversations on Commercialization: Changing the Name Game with Addison Whitney’s Ari™

15

CNS Summit Series: Can Psychedelics Reshape Psychiatry? A Conversation with Kabir Nath, CEO, Compass Pathways

16

Conversations on Commercialization: GLP-1 Gold Rush — Who’s Really Winning in the New Obesity Market?

17

Conversations on Commercialization: DTP, AI and the Future of Pharma Access

18

Conversations on Commercialization: The New Rules of HCP Engagement

19

2025 Health Trends | Getting Real About Omnichannel: A View from the Leading Edge

20

Asembia AXS25 Series: Redefining Access for Enhanced Retail Therapies, with Cheryl Allen of Curatio Advisors

21

Asembia AXS25 Series: Reimagining Patient Support: Scaling Access, Affordability and AI Integration with Kelly Carter of Amgen

22

Asembia AXS25 Series: Redefining Market Access: Patient Support, Technology and Pharma Strategy with Rob Truckenmiller of PharmaCord

23

Asembia AXS25 Series: Holistic Patient Support with Tiara Green of Accessia Health

24

Asembia AXS25 Series: Modernizing Patient Services: AI, Hybrid Models and Innovation Strategy with Greg Morris of CareMetx

25

Project Optimus Series: Clinical Pharmacology and Project Optimus

26

2025 Health Trends | Strategy, Agility and Innovation in Launch Excellence

27

2025 Health Trends | AI as an R&D Investment

28

Asembia AXS25 Series: Navigating Modern Market Access

29

Project Optimus Series: The Role of Biostatistics

30

Project Optimus Series: Operationalizing Dose Optimization

31

Opportunities Abound for PDTs, with Click Therapeutics

32

Unlocking the Black Box of Psychiatric Clinical Research, with Dr. Rishi Kakar of Segal Trials

33

Project Optimus Series: The Regulatory Implications of Project Optimus

34

CNS Summit Series: Pioneering Patient Advocacy, with Ryan Brooks from CenExel

35

CNS Summit Series: Future-Proofing Clinical Trials

36

CNS Summit Series: Pioneering Psychiatry - Behind the Breakthrough KarXT with Dr. Stephen Brannan

37

CNS Summit Series: Decoding Biology to Radically Change the Lives of Patients, with Dr. Najat Khan of Recursion Pharma

38

CNS Summit Series: Schizophrenia, Clinical Trials and Hope, with Dr. David Walling of Cenexel CNS

39

CNS Summit Series: The Future of Immunology and Personalized Health,with Jane Metcalfe of The Human Immunome Project

40

CNS Summit Series: Psychedelics and Beyond, with Kevin Craig of atai Life Sciences

41

CNS Summit Series: Redefining Psychiatry with Science and Compassion, with Dr. David Brown of Community Clinical Research

42

CNS Summit Series: Patient-Centric Innovation at Scale, with Cristina Duran of Evinova

43

CNS Summit Series: Celebrating 15 Years of Innovation with Dr. Amir Kalali of CNS Summit

44

Project Optimus Series: Navigating the Realities of Project Optimus

45

Psychedelics 3.0: Challenges and Opportunities in an Evolving Field

46

A Site-Specific Approach to Optimizing Diversity in Oncology Trials

47

Circulating Tumor DNA: Transforming Oncology Clinical Trials

48

Cashing in on the Currency of Information

49

Decoding Gen AI’s Potential to Drive More Effective Clinical Trials

50

Connecting the Global Dots on Carbon Footprint in Biopharma

51

Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?

52

Unpacking the Role of Adjuvant Therapies in Breast Cancer

53

Site and Study Execution for Ophthalmology Trials

54

The Case for Genetic Medicines

55

Jeff Stewart Says Goodbye

56

Patient Assistance: The Best Deal in Pharma

57

Real Talk About the Inflation Reduction Act

58

Turbo-Charging Clinical Trials

59

Investing for Commercial Success as an Emerging Company

60

Ophthalmology Clinical Trials: Low Vision and AMD Awareness Month

61

FDA Rules for Radio & TV Advertising

62

2024 Health Trends: Managing the Healthcare Revolution

63

World Mental Health Day: The State of Mental Health Clinical Development

64

Radiosensitizers in Head and Neck Cancer

65

Market Access for Weight Loss Drugs

66

Training MSLs in the Metaverse

67

Biopharma and the Emergency Department

68

Biotech Value Creation

69

2023 Health Trends: Improved Sophistication in Retention

70

Digital Therapeutic Development and Approval

71

Digital Therapeutic Commercialization

72

Cancer: The Patient Perspective

73

2023 Health Trends: The Data Effect

74

2023 Health Trends: A New Field for the Field Force

75

2023 Health Trends: Digital Transformation: Start, Stall, Restart

76

Gene Therapy for Hemophilia

77

The Inflation Reduction Act

78

2023 Health Trends: AI: Finally Fit for Purpose

79

2023 Health Trends: AgeTech with Musician, Actor and Patient Advocate James Ian

80

Reg Ops Edition: Attracting and Retaining Talent

81

Life Sciences Dealmaking: Dealmakers' Intentions 2023

82

2023 Health Trends: Personally, Purposefully Building What’s Next

83

Real World Evidence and Rare Diseases, Part 3: The Value of Registries

84

Decentralized Clinical Trials: Implications for Biotech

85

Full-Service Commercial

86

MAPS Edition: Value Demonstration - A View From the Top

87

MAPS Edition: Bringing Medical Affairs Into the C-Suite

88

Opportunities and Challenges in Cell and Gene Therapy

89

MAPS Edition: Recruiting for the New Profile of Medical Affairs

90

MAPS Edition: Stakeholder Engagement in a Data-Driven Environment

91

MAPS Edition: Measuring the Immeasurable: Value and Impact of Medical Affairs

92

MAPS Edition: Be Bold - Preparing Medical Affairs for 2030 and Beyond

93

Training the Next Generation of Pharma

94

Getting Access

95

Epilepsy, the Central Nervous System and Rare Disease

96

The Placebo Effect

97

Mental Health in Rare Disease

98

Navigating the Rare Disease Landscape

99

Business Continuity Through Strategic Outsourcing

100

The Virtual Sales Organization

101

Thirty Years of Physician Answers

102

Syneos Short: Talking to Our Families About COVID-19 Vaccines

103

2021 HEALTH TRENDS EDITION: Leading Change in China

104

2021 HEALTH TRENDS EDITION: Field Force of the Future

105

2021 HEALTH TRENDS EDITION: Omnichannel Experience

106

Storytelling in Pharma

107

2021 HEALTH TRENDS EDITION: Remote Care in 2021 and Beyond

108

Virtual Pharma

109

Pharmacovigilance in the COVID-19 Era and Beyond

110

Lifecycle Management

111

Source Document Review in the Modern World

112

Learning Agility in Medical Affairs

113

Trade and Distribution in Pharma: It's Complicated

114

Peter Kolchinsky and Investing in Biopharma

115

Peter Kolchinsky and The Great American Drug Deal

116

Real World Evidence and Rare Diseases

117

Global Pharma

118

APAC EDITION: Clinical Development in Japan

119

Learning Agility

120

China vs. Cancer

121

Rapid Early Phase Clinical Trials

122

Payer Power, Part 3

123

CORONAVIRUS SPECIAL EDITION, Episode 12: COVID-19 and Children

124

CORONAVIRUS SPECIAL EDITION, Episode 11: Rare Disease Clinical Trials and COVID-19

125

NEWYORKBIO BIOPHARMA INNOVATORS SERIES: Yelp Ratings for Clinical Trials

126

NEWYORKBIO BIOPHARMA INNOVATORS SERIES: Taming the Healthcare Data Explosion

127

NEWYORKBIO BIOPHARMA INNOVATORS SERIES: Real World Data for Clinical Innovation

128

CORONAVIRUS SPECIAL EDITION, Episode 10: Ventilating the COVID-19 Patient

129

CORONAVIRUS SPECIAL EDITION, Episode 9: Telemedicine in the Age of COVID-19

130

CORONAVIRUS SPECIAL EDITION, Episode 8: Payers and COVID-19

131

CORONAVIRUS SPECIAL EDITION, Episode 7: Continuity in Clinical Trials

132

CORONAVIRUS SPECIAL EDITION, Episode 6: The Leader's Experience

133

CORONAVIRUS SPECIAL EDITION, Episode 5: Surviving the Ventilator Shortage

134

CORONAVIRUS SPECIAL EDITION, Episode 4: Clinical Trials Through Pandemics

135

CORONAVIRUS SPECIAL EDITION, Episode 3: Virtual Clinical Trials

136

CORONAVIRUS SPECIAL EDITION, Episode 2: The Clinical Experience

137

CORONAVIRUS SPECIAL EDITION, Episode 1: The Personal Experience

138

Recruiting Patients for Clinical Trials

139

Medical Affairs Series, Part Six: Commercial Plus Medical Affairs

140

2020 Health Trends: Box Store Healthcare

141

Denials, Delays and Deep Discounts in Pharmaceutical Launch

142

Medical Affairs Series, Part Five: Medical Affairs in the Early Stage

143

Real World Evidence and Rare Diseases

144

The Digital Therapeutics Alliance: A European Perspective

145

Medical Affairs Series, Part Four: Medical Affairs in the Field

146

Medical Affairs Series, Part Three: Moving to the Left

147

Advocacy Archetypes

148

Medical Affairs Series, Part Two - Measuring the Unmeasurable: Medical Affairs Metrics

149

Why We Resist

150

Medical Affairs Series, Part One: A Foundation for Medical Affairs

151

A Regulatory Roadmap for Real World Evidence

152

Talented Teams

153

Digital Therapeutics

154

Talking About PIE

155

MOAs in ONC: The Latest and Greatest in the Oncology Pipeline

156

Episode 037: Psychology in Clinical Trials

157

Episode 036: Commercialization for Emerging Companies

158

Episode 035: How Translational Science Can Solve Pharma's Productivity Puzzle

159

Episode 034: Can the Gut Microbiome Revolutionize Medical Care?

160

APAC Edition: Medical Affairs in China

161

Episode 033: From DTC to DT"Me" - The Future of Communications in Pharmaceuticals

162

Episode 032: Navigating the New EU Medical Device Regulations

163

APAC Edition: Acceleration in Asia

164

Episode 031: Real World Evidence in Europe

165

Episode 030: Land of Opportunity: R&D in Asia Pacific

166

Episode 029: Commercial Models of the (Very Near) Future

167

Episode 028: World Cancer Day

168

Episode 027: Caregivers

169

Episode 026: The Health Trend Ten - Clinical Perspective

170

Episode 025: The Health Trend Ten - Commercial Perspective

171

Episode 024: Content that Clicks

172

Episode 023: The Clinical Trial Marathon, at a Sprint

173

Episode 022: Spending for Launch Success

174

Episode 021: The Sales Force Training (R)evolution

175

Episode 020: A Syneos Health Short - 21st Century Cures

176

Episode 019: A Decade of Dealmakers' Intentions

177

Episode 018: Partnering with a CRO

178

Episode 016: Payer Power, Part 2

179

Episode 015: ICER - Friend or Foe?

180

Episode 014: MA-"Squared": Medical Affairs Meets Market Access

181

Episode 009: Rare Diseases

182

Episode 013: Artificial Intelligence for Authentic Engagement

183

Episode 012: Medical Affairs from Zero

184

Episode 011: Naming, Part 2 - The Drug

185

Episode 010: Naming, Part 1 - The Pharma Company

186

Episode 008: Social Centricity

187

Episode 007: Medicine in 140 Characters: Digital KOLs

188

Episode 006: Crossing the Finish Line: Factors Driving Patient Adherence to Drug Therapy

189

Episode 005: The Room Where it Happens: Dealmakers' Intentions 2017

190

Episode 004: Innovation in Pharma Communications

191

Episode 003: Payer Power

192

Episode 002: The Impact of AHCA on Pharma

193

Episode 001: The Real-World Evidence Revolution